RT Journal Article
SR Electronic
T1 The contribution of de novo coding mutations to meningomyelocele
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.28.24303390
DO 10.1101/2024.02.28.24303390
A1 Ha, Yoo-Jin
A1 Tang, Isaac
A1 Nisal, Ashna
A1 Jhamb, Ishani
A1 Wallace, Cassidy
A1 Schroeder, Sarah
A1 Lee, Chanjae
A1 Vong, Keng loi
A1 Meave, Naomi
A1 Jiwani, Fiza
A1 Barrows, Chelsea
A1 Lee, Sangmoon
A1 Jiang, Nan
A1 Patel, Arzoo
A1 Blanco, Francisco A.
A1 Yu, Seyoung
A1 Jeong, Hui Su
A1 Plutzer, Isaac
A1 Major, Michael B.
A1 Benoit, Béatrice
A1 Poüs, Christian
A1 Heffner, Caleb
A1 Kibar, Zoha
A1 Bot, Gyang Markus
A1 Northrup, Hope
A1 Au, Kit Sing
A1 Strain, Madison
A1 Ashley-Koch, Allison
A1 Finnell, Richard H.
A1 Le, Joan T.
A1 Meltzer, Hal
A1 Araujo, Camila
A1 Machado, Helio R.
A1 Stevenson, Roger E.
A1 Yurrita, Anna
A1 Mumtaz, Sara
A1 Mutchinick, Osvaldo M.
A1 Medina-Bereciartu, José Ramón
A1 Hildebrandt, Friedhelm
A1 Melikishvili, Gia
A1 Marwan, Rony
A1 Capra, Valeria
A1 Noureldeen, Mahmoud M.
A1 Salem, Aida M.S.
A1 Issa, Mahmoud Y.
A1 Zaki, Maha S.
A1 Lee, Ji Eun
A1 Alkelai, Anna
A1 Shuldiner, Alan R.
A1 Kingsmore, Stephen F.
A1 Murray, Stephen A.
A1 Gee, Heon Yung
A1 Miller, W. Todd
A1 Tolias, Kimberley F.
A1 Wallingford, John B.
A1 Spina Bifida Sequencing Consortium
A1 Kim, Sangwoo
A1 Gleeson, Joseph G.
YR 2024
UL http://medrxiv.org/content/early/2024/03/02/2024.02.28.24303390.abstract
AB Meningomyelocele (MM) is considered a genetically complex disease resulting from failure of neural tube closure (NTD). Patients display neuromotor disability and frequent hydrocephalus requiring ventricular shunting. A few proposed genes contribute to disease susceptibility, but most risk remains unexplained1. We postulated that de novo mutations (DNMs) under purifying selection contribute to MM risk2. Here we recruited a cohort of 851 MM trios requiring shunting at birth, compared with 732 control trios, and found that de novo likely gene disrupting or damaging missense mutations occur in approximately 22.3% of subjects, 28% of which are estimated to contribute to disease risk. The 187 genes with damaging DNMs collectively define networks including actin cytoskeleton and microtubule-based processes, axon guidance, and histone modification. Gene validation demonstrates partial or complete loss of function, impaired signaling and defective neural tube closure in Xenopus embryos. Our results suggest DNMs make key contributions to MM risk, and highlight critical pathways required for neural tube closure in human embryogenesis.Competing Interest StatementAA and ARS are full time employees of Regeneron Genetics Center. SK is cofounder of AIMA Inc., which seeks to develop techniques for early cancer diagnosis based on circulating tumor DNA.Clinical Protocols https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwj71f7c8smEAxVbH0QIHcymDkMQFnoECBIQAQ&url=https%3A%2F%2Fneurosciences.ucsd.edu%2Fresearch%2Flabs%2Fgleeson%2Fspinabifida%2Findex.html&usg=AOvVaw33KDWLhNIDZeATDXvR_5h0&opi=89978449 Funding StatementThis work was funded by the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All subjects or their guardians provided written informed consent approved by the UCSD Institutional Review Board S99075 protocol 140028, expiration date Aug 1, 2024. Recruitment processes were conducted in accordance with the approval by review boards of the University of California San Diego, operating under Federal-wide Assurance number, FWA00004495. The above rulings cover all aspects of our study, not just recruitment and consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesExome and genome sequencing data are available in publicly accessible databases for the 1,576 subjects enrolled after inclusion of dbGaP language into the consenting process/ became standard. These data are at dbGaP (accession #phs002591.v1.p1, phs000744.v5.p2 (Yale Mendelian Sequencing Center), Kids First: Whole Genome Sequencing in Structural Defects of the Neural Tube Accession (phs002591.v1.p1).Sequencing data on the remaining 743 subjects is available upon request.